Track market-moving stories before they get noisy

Posted by Defense World Staff on Aug 8th, 2026

Empowered Funds LLC increased its holdings in DENTSPLY SIRONA Inc. (NASDAQ:XRAY – Free Report) by 515.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 126,601 shares of the medical instruments supplier’s stock after acquiring an additional 106,024 shares during the quarter. Empowered Funds LLC owned approximately 0.06% of DENTSPLY SIRONA worth $1,469,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. First Eagle Investment Management LLC grew its position in shares of DENTSPLY SIRONA by 3.2% in the 4th quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock worth $167,342,000 after buying an additional 458,744 shares during the last quarter. AQR Capital Management LLC boosted its holdings in DENTSPLY SIRONA by 109.8% in the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after acquiring an additional 6,970,086 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in DENTSPLY SIRONA by 0.9% in the third quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier’s stock worth $129,445,000 after acquiring an additional 92,868 shares in the last quarter. Southpoint Capital Advisors LP purchased a new position in shares of DENTSPLY SIRONA in the 1st quarter valued at approximately $116,000,000. Finally, Armistice Capital LLC raised its holdings in shares of DENTSPLY SIRONA by 27.2% in the fourth quarter. Armistice Capital LLC now owns 7,298,000 shares of the medical instruments supplier’s stock worth $83,416,000 after buying an additional 1,562,000 shares during the last quarter. 95.70% of the stock is currently owned by institutional investors.

Insider Activity at DENTSPLY SIRONA In other news, Director Brian P. Mckeon purchased 10,000 shares of the company’s stock in a transaction dated Friday, June 12th. The stock was acquired at an average price of $10.12 per share, with a total value of $101,200.00. Following the purchase, the director directly owned 10,000 shares in the company, valued at approximately $101,200. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Brian T. Gladden acquired 9,985 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was acquired at an average price of $10.02 per share, for a total transaction of $100,049.70. Following the completion of the acquisition, the director directly owned 61,849 shares of the company’s stock, valued at $619,726.98. The trade was a 19.25% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders purchased 35,160 shares of company stock valued at $351,179. 0.46% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth Several analysts have weighed in on the company. Citigroup initiated coverage on DENTSPLY SIRONA in a research note on Wednesday, April 15th. They set a “sell” rating and a $10.00 price target on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research report on Monday. Mizuho dropped their price objective on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Barclays cut their price objective on shares of DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a research note on Thursday, June 4th. Finally, UBS Group decreased their target price on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Three analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $13.54.

Read Our Latest Stock Report on XRAY

DENTSPLY SIRONA Stock Down 8.0% Shares of NASDAQ XRAY opened at $12.12 on Friday. The firm has a market cap of $2.43 billion, a price-to-earnings ratio of -4.41, a price-to-earnings-growth ratio of 1.57 and a beta of 0.85. The company’s 50-day simple moving average is $11.77 and its 200-day simple moving average is $11.89. The company has a quick ratio of 0.98, a current ratio of 1.53 and a debt-to-equity ratio of 1.52. DENTSPLY SIRONA Inc. has a 52-week low of $9.40 and a 52-week high of $14.86.

DENTSPLY SIRONA (NASDAQ:XRAY – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.17. The firm had revenue of $898.00 million during the quarter, compared to the consensus estimate of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.74%. The company’s revenue for the quarter was down 4.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.52 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities analysts predict that DENTSPLY SIRONA Inc. will post 1.42 EPS for the current fiscal year.

DENTSPLY SIRONA News Summary Here are the key news stories impacting DENTSPLY SIRONA this week:

Positive Sentiment: Adjusted earnings exceeded expectations: Q2 EPS was $0.52, above analyst estimates ranging from $0.35 to $0.36 and matching the year-ago result. Revenue of $898 million also surpassed the roughly $890 million consensus. Dentsply International Beats Q2 Earnings and Revenue Estimates Positive Sentiment: Margins improved: Management highlighted better margins during the quarter, helping offset softer demand and supporting the earnings beat. The Wellspect business was a key sales-growth contributor. XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales Neutral Sentiment: Full-year EPS guidance was maintained: DENTSPLY SIRONA reiterated 2026 adjusted EPS guidance of $1.40 to $1.50, which brackets the approximately $1.42 analyst consensus. DENTSPLY SIRONA Second-Quarter 2026 Results Negative Sentiment: Sales declined year over year: Q2 revenue fell 4.1%, as weakness in the company’s core dental business outweighed growth at Wellspect. This suggests that broader dental-market demand and utilization remain pressured. XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales Negative Sentiment: Revenue guidance was cautious: The company forecast 2026 revenue of $3.5 billion to $3.6 billion, with the midpoint below the $3.6 billion consensus estimate. Investors appear to be prioritizing the weak organic-sales trend and outlook over the quarterly EPS beat. DENTSPLY SIRONA Company Profile (Free Report)

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

Recommended Stories Five stocks we like better than DENTSPLY SIRONA Datadog’s Drop Says More About Expectations Than Earnings D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus Solventum Nears Inflection Point As It Begins to Unlock Value

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEDai ichi Life Insurance Company Ltd Acquires 12,401 Shares of Amazon.com, Inc. $AMZN

NEXT HEADLINE »Empowered Funds LLC Raises Holdings in Snap Inc. $SNAP

Key Takeaways XRAY's Q2 revenues fell 4.1% to $898M as weakness in three dental segments weighed on sales.Wellspect Healthcare sales rose 7.1% to $86M, supported by new product launches.XRAY maintained 2026 sales guidance of $3.5-$3.6B and adjusted EPS outlook of $1.40-$1.50. DENTSPLY SIRONA Inc. (XRAY - Free Report) reported second-quarter 2026 adjusted earnings per share (EPS) of 52 cents, down 1.6% year over year on an actual-value basis. The bottom line beat the Zacks Consensus Estimate of 36 cents by 44.4%.

GAAP EPS in the quarter was 18 cents against loss per share of 22 cents in the prior-year quarter.

XRAY's Revenue Trends and Regional MixRevenues declined 4.1% reportedly to $898 million and 6.3% at constant currency (cc). The metric, however, beat the Zacks Consensus Estimate by 1.6%.

Weakness across three dental segments weighed on sales, partly offset by Wellspect Healthcare growth and a 1.8% negative impact from Byte.

Shares of XRAY declined 1.9% in yesterday’s after-market trading. The stock has gained 15.2% year to date compared with the industry’s 4.8% increase. The S&P 500 Index has increased 12.7% in the same period.

Image Source: Zacks Investment Research

Dentsply Sirona's Segment PerformanceDENTSPLY SIRONA generates revenues under four segments — Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare.

Connected Technology Solutions revenues totaled $239 million, down 1.5% year over year and 3.8% at constant currency. Lower CAD/CAM volumes in the Americas and unfavorable price mix in EMEA weighed on results, partly offset by double-digit APAC growth. Equipment and Instruments also faced lower Treatment Center volumes. Our projection was $218 million for the metric.

Essential Dental Solutions generated $376 million in revenues, down 2.7% reportedly and 5% at cc. Our projection was $367.8 million for the metric.

Orthodontic and Implant Solutions sales declined 13.2% to $197 million, reflecting an $18 million Byte headwind and lower orthodontic and implant volumes. Our projection was $211.2 million for the metric.

Wellspect Healthcare was the bright spot, with revenues rising 7.1% to $86 million, supported by new product launches. Our projection was $87.8 million for the metric.

DENTSPLY SIRONA’s Geographic RevenuesBeginning first-quarter 2026, DENTSPLY SIRONA started reporting under new regional segments — North and South America as Americas, Europe, the Middle East, and Africa (“EMEA”) and Asia Pacific (“APAC”). The company used to report under US, Europe and Rest of World geographic segments.

Americas revenues fell 10.7% as reported and 11.6% at cc.

EMEA sales edged up 0.2% on a reported basis but declined 3.6% at cc.

APAC revenues slipped 1% as reported and 1.2% at cc.

XRAY's Margin and Expense PictureAdjusted gross profit was $506 million compared with $523 million a year earlier. Still, adjusted gross margin improved 50 bps to 56.4%. The quarter benefited from tariff refunds, though lower volumes, unfavorable mix and tariff costs pressured gross profit. We had projected an adjusted gross margin of 53.7% for the second quarter.

Selling, general and administrative expenses increased 6.4% year over year to $364 million, while research and development expenses rose 21.6% to $45 million.

Adjusted operating profit totaled $142 million, reflecting a 16.5% decrease from the prior-year quarter’s level. The adjusted operating margin contracted 240 bps to 15.8%.  We had projected an adjusted operating margin of 12.8% for the second quarter.

Adjusted EBITDA declined 3.3% to $190 million. Adjusted EBITDA margin expanded 20 basis points (bps) to 21.3%.

Dentsply Sirona's Cash Flow and LiquidityXRAY ended June with $239 million in cash and cash equivalents, down from $326 million in the first quarter.

Cumulative net cash provided by operating activities at the end of the second quarter of 2026 was $139 million compared with $55 million in the prior-year period. The improvement primarily reflected approximately $44 million of tariff refunds and better inventory and accounts-payable management. Free cash flow during the second quarter increased to $55 million from $16 million.

During the quarter, the company repurchased 1.3 million common shares for roughly $12 million, advancing its capital-allocation efforts while maintaining its focus on working-capital improvement.

DENTSPLY SIRONA has a consistent dividend-paying history, with its five-year annualized dividend growth being 9.5%.

XRAY's 2026 Outlook and Strategic ProgressDENTSPLY SIRONA maintained its 2026 net sales outlook of $3.5 billion to $3.6 billion and adjusted EPS guidance of $1.40-$1.50. The expected benefits from tariff refunds are not included in the adjusted earnings outlook. The Zacks Consensus Estimate for sales and adjusted EPS is currently pegged at $3.58 billion and $1.42, respectively.

The company continued to execute its Return-to-Growth Action Plan, focusing on strengthening distributor relationships, realigning sales teams, and reinvesting in the business. It also expanded its partnership with Medline Sinclair in Canada, marking the sixth enhancement to its distribution network announced in 2026. Additionally, John Fortson assumed the role of executive vice president and chief financial officer in July 2026.

XRAY’s Zacks Rank & Key PicksDENTSPLY SIRONA currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , The Cooper Companies (COO - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

West Pharmaceutical reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

West Pharmaceutical has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.40%.

The Cooper Companies reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10.00%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.

The Cooper Companies has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.80%.

Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.

Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.27%.

News Summary

Reported net sales of $898 millionDelivered GAAP gross margin of 54.9%, GAAP diluted earnings per share of $0.18Achieved adjusted gross margin of 56.4%, adjusted EBITDA margin of 21.3%, adjusted EPS of $0.52Announced expanded partnership with Medline Sinclair, broadening access to Connected Technology Solutions portfolio across CanadaRepurchased 1.3 million shares of common stock during the quarterReiterates 2026 outlook for net sales and adjusted EPS CHARLOTTE, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the second quarter of 2026.

"2026 continues to be a year of decisive action as we execute our Return-to-Growth Action Plan," said Dan Scavilla, President and Chief Executive Officer of Dentsply Sirona. "We are making meaningful progress in our highest priority areas, including strengthening and expanding our distributor relationships, realigning our sales teams, and reinvesting in the business. Our second quarter results were in line with expectations and we continue to strengthen the financial foundation of the company. As our work gains traction, we remain focused on executing our strategy with discipline to drive sustained, profitable growth."

Q2 2026 Summary Results (Reported)

(in millions, except per share amount and percentages) Q2 26 Q2 25 YoYNet Sales $898 $936 (4.1%)Gross Profit $493 $490 0.6%Gross Margin 54.9% 52.4%  Net Income (Loss) Attributable to Dentsply Sirona $37 ($45)
 NMDiluted Earnings (Loss) Per Share1 $0.18 ($0.22)
 NM        Q2 2026 Summary Results (Non-GAAP)

(in millions, except per share amount and percentages) Q2 26 Q2 25 YoYConstant Currency Sales     (6.3%)Adjusted EBITDA $190 $197 (3.3%)Adjusted EBITDA Margin 21.3% 21.1%  Adjusted EPS $0.52 $0.52 (1.6%)       
NM - not meaningful
Percentages are based on actual values and may not reconcile due to rounding.
[1] Weighted-average shares outstanding used to calculate diluted loss per share for the second quarter of 2025 excludes potential dilutive common shares.

Q2 2026 Results by Region and Segment (Reported and Non-GAAP)
(in millions, except percentages)

     Percentage ChangeNet Sales by Segment  Three Months Ended June 30,
2026 vs. 2025        Americas EMEA APAC                 2026
 2025
 As
Reported1Constant
Currency1 As
ReportedConstant
Currency As
ReportedConstant
Currency As
ReportedConstant
Currency                Connected Technology Solutions$        239 $        243 (1.5)%(3.8)% (7.5)%(9.4)% (2.1)%(5.7)% 8.8%9.5%Essential Dental Solutions           376            387 (2.7)%(5.0)% (2.2)%(3.0)% (3.9)%(8.0)% 0.2%(0.8)%Orthodontic and Implant Solutions            197            226 (13.2)%(14.9)% (27.1)%(27.6)% 2.0%(1.5)% (14.9)%(15.6)%Wellspect Healthcare             86              80  7.1%3.8% (22.5)%(20.9)% 11.9%7.8% 9.6%15.2%Total$        898  $        936 (4.1)%(6.3)% (10.7)%(11.6)% 0.2%(3.6)% (1.0)%(1.2)%(1) Constant currency sales are a Non-GAAP measure in which the reported net sales are adjusted for the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period's currency exchange rates. The foreign currency impact is the only reconciling item between as reported and constant currency sales.  Cash Flow and Liquidity

Operating cash flow in the second quarter of 2026 was $99 million, compared to $48 million in the second quarter of 2025, primarily due to the receipt of approximately $44 million in tariff refunds and improved management of inventory and accounts payable. Free cash flow, a Non-GAAP measure, in the second quarter of 2026 was $55 million compared to $16 million in the second quarter of 2025. The Company repurchased 1.3 million shares of its common stock for a total of approximately $12 million in the second quarter of 2026. The Company had $239 million of cash and cash equivalents as of June 30, 2026.

2026 Outlook

The Company is maintaining its 2026 outlook for net sales in the range of $3.5 billion to $3.6 billion and adjusted EPS in the range of $1.40 to $1.50. The benefits of refunds for tariffs are not included in the outlook for 2026 adjusted EPS.

We are unable to present a quantitative reconciliation of our expected earnings per diluted share to expected adjusted earnings per diluted share as we are unable to predict with reasonable certainty and without unreasonable effort, items which may include, but are not limited to, restructuring charges, transformation-related costs, impairment charges, certain tax adjustments, and other significant items. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Operations.

Conference Call/Webcast Information
Dentsply Sirona's management team will host an investor conference call and live webcast on August 6, 2026, at 4:30 p.m. ET. The live webcast and a presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com.

For those planning to participate on the call, please register at https://register-conf.media-server.com/register/BIa20adbc738174810a6f4b3ce44466cfa. A webcast replay of the conference call will be available on the Investors section of the Company's website following the call.

About Dentsply Sirona
Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering, including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona's innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company's shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

Contact Information:
Investors:
Wade Moody
Senior Manager, Investor Relations
[email protected]

Press:
Marion Par-Weixlberger
Vice President, Public Relations, Corporate Communications & Brand
[email protected]

Forward-Looking Statements and Associated Risks

All statements in this Press Release that do not directly and exclusively relate to historical facts constitute "forward-looking statements." Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control, including those described in Part I, Item 1A, "Risk Factors" of the Company's most recent Annual Report on Form 10-K, Part II, Item 1A, "Risk Factors" of the Company's Quarterly Reports on Form 10-Q for any subsequent fiscal quarters, and any updating information or other factors which may be described in the Company's other filings with the Securities and Exchange Commission (the "SEC"). No assurance can be given that any expectation, belief, goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this Press Release or to reflect the occurrence of unanticipated events. Investors should understand it is not possible to predict or identify all such factors or risks. As such, you should not consider the risks identified in the Company's SEC filings to be a complete discussion of all potential risks or uncertainties associated with an investment in the Company.

DENTSPLY SIRONA INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(in millions, except per share amounts)
(unaudited)

 Three Months Ended June 30, Six Months Ended June 30, 2026
 2025
 2026
 2025
Net sales$898  $936  $1,778  $1,815 Cost of products sold 405   446   858   859         Gross profit 493   490   920   956         Selling, general, and administrative expenses 364   342   715   700 Research and development expenses 45   37   89   73 Goodwill and intangible asset impairments —   235   —   235 Restructuring and other costs 2   4   69   13         Operating income (loss) 82   (128)  47   (65)        Other income and expenses:       Interest expense, net 22   24   46   43 Other (income) expense, net (12)  1   (29)  1         Income (loss) before income taxes 72   (153)  30   (109)Provision (benefit) for income taxes 36   (109)  4   (84)        Net income (loss) 36   (44)  26   (25)        Less: Net (loss) income attributable to noncontrolling interest (1)  1   (1)  —         Net income (loss) attributable to Dentsply Sirona$37  $(45) $27  $(25)        Earnings (loss) per common share attributable to Dentsply Sirona:       Basic$0.18  $(0.22) $0.14  $(0.13)Diluted$0.18  $(0.22) $0.14  $(0.13)        Weighted average common shares outstanding:       Basic 199.7   199.3   199.8   199.2 Diluted 200.5   199.3   200.8   199.2                  DENTSPLY SIRONA INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions, except share and per share amounts)
(unaudited)

 June 30, 2026 December 31, 2025    Assets   Current Assets:   Cash and cash equivalents$239 $326Accounts and notes receivable-trade, net 620  688Inventories, net 665  642Prepaid expenses and other current assets 404  367Total Current Assets 1,928  2,023    Property, plant, and equipment, net 845  861Operating lease right-of-use assets, net 129  139Identifiable intangible assets, net 870  974Goodwill 1,138  1,148Other noncurrent assets 294  284Total Assets$5,204 $5,429    Liabilities and Equity   Current Liabilities:   Accounts payable$260 $300Accrued liabilities 664  700Income taxes payable 33  30Notes payable and current portion of long-term debt 228  313Total Current Liabilities 1,185  1,343    Long-term debt 1,996  2,015Operating lease liabilities 88  93Deferred income taxes 79  94Other noncurrent liabilities 505  544Total Liabilities 3,853  4,089    Total Equity 1,351  1,340    Total Liabilities and Equity$5,204 $5,429     DENTSPLY SIRONA INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions)
(unaudited)

 Six Months Ended June 30, 2026
 2025
    Cash flows from operating activities:   Net income (loss)$26  $(25)    Adjustments to reconcile net loss to net cash provided by operating activities:   Depreciation 74   68 Amortization of intangible assets 90   99 Goodwill asset impairment —   156 Indefinite-lived intangible asset impairment —   79 Deferred income taxes (42)  (136)Stock-based compensation expense 17   19 Other non-cash (income) expense (13)  19 Gain on disposal of assets (6)  — Changes in operating assets and liabilities:   Accounts and notes receivable-trade, net 56   (31)Inventories, net (32)  (47)Prepaid expenses and other current assets (11)  26 Other noncurrent assets (2)  1 Accounts payable 16   (10)Accrued liabilities (38)  (35)Income taxes 4   (55)Other noncurrent liabilities —   (73)Net cash provided by operating activities 139   55     Cash flows from investing activities:   Capital expenditures (96)  (51)Cash received on derivative contracts —   1 Cash paid on derivative contracts —   (2)Net investment hedge settlements (8)  — Proceeds from sale of property, plant, and equipment 5   1 Other investing activities 7   — Net cash used in investing activities (92)  (51)    Cash flows from financing activities:   Cash paid for treasury stock (12)  — Proceeds from 364-day bridge loan —   435 Repayment of 364-day bridge loan —   (435)Repayments on short-term borrowings (50)  (413)Cash dividends paid (32)  (64)Proceeds from long-term borrowings —   550 Repayments on long-term borrowings (31)  (2)Cash paid for deferred financing costs —   (13)Other financing activities, net (5)  (3)Net cash (used in) provided by financing activities (130)  55 Effect of exchange rate changes on cash and cash equivalents (4)  28 Net (decrease) increase in cash and cash equivalents (87)  87 Cash and cash equivalents at beginning of period 326   272 Cash and cash equivalents at end of period$239  $359     Supplemental disclosures of cash flow information:   Interest paid, net of amounts capitalized$43  $43 Non-cash investing activities:   Property, plant and equipment in accounts payable at end of period$19  $25 Exchange of inventory for naming and other rights$—  $14          Supplemental Information – Reconciliation of GAAP to Non-GAAP Financial Measures

We supplement the reporting of our financial information determined under accounting principles generally accepted in the United States ("GAAP") with certain non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; adjusted gross profit as a percent of net sales ("Adjusted Gross Margin"); adjusted operating income; adjusted operating income as a percent of net sales ("Adjusted Operating Margin"); adjusted earnings before interest expense, income taxes, depreciation and amortization ("Adjusted EBITDA"); Adjusted EBITDA as a percent of net sales ("Adjusted EBITDA Margin"); adjusted net income (loss); adjusted earnings (loss) per diluted share ("Adjusted EPS"); and Free Cash Flow. These non-GAAP financial measures are used by the Company to measure its performance and management believes these non-GAAP financial measures provide meaningful information to assist investors and shareholders in understanding our financial results and assessing our prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of our operations because they exclude items that may not be indicative of or are unrelated to our core operating results and provide a baseline for analyzing trends in our underlying businesses. Management uses these non-GAAP financial measures for reviewing the operating results of reportable business segments and analyzing potential future business trends in connection with our budget process and bases certain management incentive compensation on these non-GAAP financial measures.

The Company has defined the non-GAAP measures used by management as follows:

Constant Currency: reported net sales adjusted for the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable period's foreign currency exchange rates.Adjusted Operating Income and Margin: Adjusted operating income is computed by excluding the following items from operating income (loss) as reported in accordance with US GAAP. Adjusted operating margin is calculated by dividing adjusted operating income by net sales. Business combination-related costs: costs related to consummating and integrating acquired businesses, as well as net gains and losses related to disposed businesses. Costs include the post-acquisition roll-off of fair value adjustments recorded related to business combinations, except for amortization expense of purchased intangible assets noted below.Restructuring-related charges and other costs: costs related to the implementation of restructuring initiatives, including but not limited to, severance costs, facility closure costs, and lease and contract termination costs, as well as related professional service costs associated with these restructuring initiatives and global transformation activity. Other costs include gains and losses on the sale of property, legal settlements, executive separation costs, write-offs of inventory as a result of product rationalization, and changes in accounting principles recorded within the period. This category also includes costs related to investigations and associated legal cases and remediation activities, which primarily include legal, accounting and other professional service fees, as well as turnover and other employee-related costs.Goodwill and intangible asset impairments: include charges related to goodwill and intangible asset impairments.Amortization of purchased intangible assets: includes the periodic amortization expense related to purchased intangible assets, which are recorded at fair value.Fair value and credit risk adjustments: include the non-cash mark-to-market changes in fair value associated with pension assets and obligations, the credit risk component of hedging instruments, contingent consideration from past acquisitions, and equity-method investments. Adjusted Gross Profit and Margin: gross profit excluding the impact of any of the above adjustments that affect either net sales or cost of sales.  Adjusted gross margin is calculated by dividing adjusted gross profit by net sales.Adjusted Net Income (Loss): net income (loss) as reported in accordance with US GAAP, adjusted to exclude the items identified above and the related income tax impacts of those items, as well as the tax effects of certain significant and discrete tax adjustments, including benefits and provisions related to changes in realization of deferred tax assets and tax credit carryforwards, as well as other events that affect comparability and are not core to our underlying operational performance.Adjusted EBITDA and Margin: in addition to the adjustments described above in arriving at adjusted net income, adjusted EBITDA is computed by further excluding any remaining interest expense, net, income tax expense, depreciation and amortization.  Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by net sales.Adjusted Earnings (Loss) Per Diluted Share: computed by dividing adjusted earnings (loss) attributable to Dentsply Sirona stockholders by the diluted weighted average number of common shares outstanding.Free Cash Flow: net cash provided by operating activities minus capital expenditures during the same period. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the reconciliations to corresponding GAAP financial measures below, provide a more complete understanding of our business. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. 

The following reconciles the non-GAAP financial measures discussed above with the most directly comparable GAAP financial measures. The weighted-average diluted shares outstanding used in the calculation of adjusted net earnings per diluted share are the same as those used in the calculation of reported net earnings per diluted share for the respective period. The weighted-average diluted shares outstanding used in the calculation of adjusted net loss per diluted share excludes potential dilutive common shares.

DENTSPLY SIRONA INC. AND SUBSIDIARIES
(in millions, except per share amounts and percentages)
(unaudited)

Beginning in fiscal year 2026, the Company updated its definition of Adjusted Net Income (Loss), a non-GAAP financial measure, to include adjustments for certain significant and discrete tax items, including benefits and provisions related to changes in the realization of deferred tax assets and tax credit carryforwards, as well as other tax‑related items that affect comparability and are not considered part of the Company's core operational performance. Prior-period information below has been updated to conform to current period presentation. A reconciliation of selected items as reported in the Condensed Consolidated Statements of Operations to adjusted Non-GAAP financial statements items are as follows:

Three Months Ended June 30, 2026 Gross Profit Operating
Income Provision for
Income Taxes Net Income
Attributable to
Dentsply Sirona Diluted
Earnings per
ShareReported $              493     $                82     $                   36  $                   37 $                0.18Reported percent net sales  54.9%  9.1%      Non-GAAP Adjustments:          Amortization of Purchased Intangible Assets                    12                        49                           12                        37                    0.18Restructuring-Related Charges and Other Costs (a)                     —                        10                             3                          7                    0.05Business Combination-Related Costs                      1                          1                            —                          1                        —Income Tax-Related Adjustments (b)                     —                         —                          (21)                       21                    0.11Adjusted $              506     $              142     $                   30  $                 103 $                0.52Adjusted percent net sales  56.4%  15.8%      Weighted average common shares outstanding used in calculating diluted GAAP net income per common share                  200.5Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share                  200.5(a) Restructuring‑Related Charges and Other Costs includes costs from restructuring actions and the new global ERP system, partially offset by a $3 change in estimate for the 2026 restructuring plan. These amounts are on a pre-tax basis.  (b) Income Tax-Related Adjustments includes adjustments for increased valuation allowances for the U.S. of $9, Switzerland of $7, Luxembourg of $5, Germany of $4, and other various tax adjustments.  Percentages are based on actual values and may not reconcile due to rounding.

Three Months Ended June 30, 2025 Gross Profit Operating
(Loss) Income (Benefit)
Provision for
Income Taxes Net (Loss)
Income
Attributable to
Dentsply Sirona Diluted (Loss)
Earnings per
ShareReported $490  $(128) $(109) $(45) $(0.22)Reported percent net sales  52.4%  (13.7%)      Non-GAAP Adjustments:          Amortization of Purchased Intangible Assets  32   54   14   40   0.20 Restructuring-Related Charges and Other Costs (a)  —   5   1   4   — Goodwill and Intangible Asset Impairments  —   235   21   214   1.07 Business Combination-Related Costs  1   4   1   3   0.01 Fair Value and Credit Risk Adjustments  —   —   —   (4)  — Income Tax-Related Adjustments (b)  —   —   107   (107)  (0.54)Adjusted $523  $170  $35  $105  $0.52 Adjusted percent net sales  55.9%  18.2%      Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share  199.3 Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share  199.9 (a) Restructuring‑Related Charges and Other Costs includes costs from various restructuring actions related to employee severance. Amounts are on a pre-tax basis.  (b) Income Tax-Related Adjustments includes adjustments for decreased valuation allowances for Luxembourg of $7, along with increased valuation allowances for Switzerland of $36 and Germany of $10, and other various tax adjustments.  Percentages are based on actual values and may not reconcile due to rounding.

DENTSPLY SIRONA INC. AND SUBSIDIARIES
(in millions, except per share amounts and percentages)
(unaudited)

Reconciliations of reported net income (loss) attributable to Dentsply Sirona to adjusted EBITDA and margin are as follows:

  Three Months Ended June 30,  2026
 2025
     Net income (loss) attributable to Dentsply Sirona $37  $(45)Interest expense, net  22   24 (Benefit) provision for income taxes  36   (109)Depreciation(1)  35   33 Amortization of intangible assets  49   54 Restructuring-related charges and other costs  10   5 Goodwill and intangible asset impairments  —   235 Business combination-related costs and fair value adjustments  1   4 Fair value and credit risk adjustments  —   (4)Adjusted EBITDA $190  $197      Net sales $898  $936 Adjusted EBITDA margin  21.3%  21.1%          (1) Excludes those depreciation-related amounts which were included as part of the business combination-related adjustments and Restructuring-related charges and other costs.
Percentages are based on actual values and may not reconcile due to rounding.

A reconciliation of free cash flow for the three months ended June 30, 2026 and 2025 is as follows:

  Three Months Ended June 30,  2026
 2025
     Net cash provided by operating activities $99  $48 Capital expenditures  (44)  (32)Free cash flow $55  $16 

Dentsply International (XRAY - Free Report) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.52 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +44.44%. A quarter ago, it was expected that this dental products manufacturer would post earnings of $0.28 per share when it actually produced earnings of $0.27, delivering a surprise of -3.57%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

Dentsply, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $898 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.60%. This compares to year-ago revenues of $936 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Dentsply shares have added about 20.6% since the beginning of the year versus the S&P 500's gain of 12.8%.

What's Next for Dentsply?While Dentsply has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Dentsply was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.37 on $866.96 million in revenues for the coming quarter and $1.42 on $3.58 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 15% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Pro-Dex, Inc. (PDEX - Free Report) , has yet to report results for the quarter ended June 2026.

This company is expected to post quarterly earnings of $0.67 per share in its upcoming report, which represents a year-over-year change of +86.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Pro-Dex, Inc.'s revenues are expected to be $19.2 million, up 9.8% from the year-ago quarter.

Key Takeaways XRAY is expected to post Q2 revenues near $884 million and adjusted EPS of 36 cents.Transformation spending, dealer inventory cuts and tariffs may pressure near-term profitability.Wellspect growth and resilient APAC demand may offset weakness in equipment, implants and Europe. DENTSPLY SIRONA Inc. (XRAY - Free Report) is scheduled to release second-quarter 2026 results on Aug. 6, after market close.

In the last reported quarter, the company’s earnings missed the Zacks Consensus Estimate by 3.57%. It delivered an average earnings surprise of negative 5.23% for the trailing four quarters.

XRAY’s Q2 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $883.9 million. The consensus mark for earnings is pinned at 36 cents per share.

Our model estimates for revenues and adjusted earnings per share (EPS) are $884.8 million and 36 cents, respectively.

Factors to Note Ahead of XRAY’s Q2 ResultsDENTSPLY SIRONA's second-quarter 2026 performance is likely to have reflected continued execution of its Return-to-Growth action plan. The company remains focused on commercial restructuring, clinical education, innovation and cost optimization during the second quarter. While these initiatives are expected to strengthen long-term growth, they are likely to have weighed on near-term profitability due to higher investments. Per the first-quarter earnings call, management also indicated that meaningful benefits from the transformation plan are expected to build gradually, with a larger impact in the second half of 2026.

The second quarter is also likely to have been affected by dealer inventory adjustments linked to the transition toward a drop-ship model. Management expects this inventory burn to occur primarily from the second quarter through the remainder of the year. This dynamic is likely to have created a revenue headwind, particularly across equipment and connected technology products. Tariff-related costs, softer implant demand and continued weakness in certain European markets are also expected to have remained pressure points during the quarter.

From a segmental standpoint, Connected Technology Solutions is likely to have remained under pressure due to softer equipment demand and dealer inventory normalization. Orthodontic and implant sales may also have stayed weak as the company continues to rebuild commercial execution in these businesses. However, Wellspect Healthcare is expected to have maintained healthy growth, supported by new product adoption. Essential Dental Solutions could also have benefited if dealer destocking trends in Europe began to moderate, as management expects.

Geographically, the U.S. business is likely to have remained the company's primary focus. Management has been expanding distributor partnerships, strengthening its sales organization and increasing customer engagement to restore growth. International markets, particularly APAC, are expected to have remained relatively resilient, while Europe is likely to have faced some pressure from inventory destocking and macro uncertainty in the to-be-reported quarter.

Investors are likely to closely watch management's commentary on the pace of U.S. recovery, dealer inventory normalization and traction from new distribution agreements. Updates on the implants turnaround, commercial execution and early adoption of recently launched products will also be in focus. Any indication that restructuring savings and revenue initiatives are beginning to contribute meaningfully in the second half of 2026 could improve investor sentiment.

What the Zacks Model Unveils for XRAYOur proven model does not conclusively predict an earnings beat for XRAY this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.

XRAY’s Earnings ESP:Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

XRAY’s Zacks Rank: DENTSPLY SIRONA currently carries a Zacks Rank #3.

Stocks to ConsiderHere are some stocks worth considering from the broader medical sector, as these have the right combination of elements to post an earnings beat this reporting cycle.

Cardinal Health (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank #2 at present. The company is set to release fourth-quarter fiscal 2026 results on Aug. 11. You can see the complete list of today’s Zacks #1 Rank stocks here.

CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%. The Zacks Consensus Estimate for CAH’s fourth-quarter EPS indicates an improvement of 16.4% from the year-ago reported figure.

Cencora (COR - Free Report) has an Earnings ESP of +1.49% and a Zacks Rank of 2 at present. The company is scheduled to release third-quarter fiscal 2026 results on Aug. 5.

COR’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 1.59%. The Zacks Consensus Estimate for COR’s fiscal third-quarter EPS implies an improvement of 9.3% from the year-ago reported figure.

Agilent Technologies (A - Free Report) has an Earnings ESP of +1.02% and a Zacks Rank #2 at present.

A’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 1.61%. The Zacks Consensus Estimate for A’s third-quarter fiscal 2026 EPS calls for an improvement of 8% from the year-ago reported figure.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Dentsply Sirona Inc. (NASDAQ: XRAY) breached their fiduciary duties to shareholders.

If you currently own Dentsply stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].

Why Your Participation Matters:

Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

July 21, 2026 16:15 ET  | Source: DENTSPLY SIRONA Inc.

CHARLOTTE, N.C., July 21, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, August 6, 2026, at 4:30 p.m. ET to review its second quarter 2026 financial results. Financial earnings materials will be made available on the Investors section of the Company’s website at https://investor.dentsplysirona.com prior to the call.

Conference Call / Webcast Information

The live webcast link and call information will be available on the Investors section of the Company’s website at https://investor.dentsplysirona.com. For those planning to participate on the call, please register here. A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call.

About Dentsply Sirona

Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona’s innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

Contact Information

Investors:
Wade Moody
Senior Manager, Investor Relations
[email protected]

This milestone reflects PDS Health’s continued investment in digital technologies that help practices operate more efficiently, expand access to same-day restorative care and deliver a more consistent experience for patients. July 01, 2026 17:00 ET  | Source: DENTSPLY SIRONA Inc.

CHARLOTTE, N.C., July 01, 2026 (GLOBE NEWSWIRE) -- PDS Health® and Dentsply Sirona today announced that PDS Health practices have surpassed five million CEREC chairside restorations, a milestone that underscores the scale, consistency and long-term integration of digital restorative workflows across supported practices nationwide.

More than a numerical achievement, the milestone reflects years of sustained clinician adoption and daily use of digital restorative technology in real-world practice settings. It also reinforces PDS Health’s position as one of the highest-volume users of chairside CAD/CAM technology with more than 1,200 CEREC systems installed across its practices. This extensive adoption demonstrates how connected digital workflows can support efficient, high-quality restorative care at scale.

“Five million chairside restorations represent millions of patients who received the care they needed without unnecessary delays or additional appointments,” said Stephen E. Thorne IV, Founder and CEO of PDS Health. “This milestone reflects decades of investment in advanced, proven technologies, clinical excellence and the support systems that help our clinicians deliver care that is more efficient, more precise and more convenient for the patients they serve. At its core, this achievement reflects our long-term commitment to improving the way care is delivered, one clinician and one patient at a time.”

Through its long-standing collaboration with Dentsply Sirona, PDS Health has continued to expand the use of digital dentistry solutions that support clinical decision-making, streamline restorative workflows and enable same-day treatment capabilities. The result is a more integrated care experience that helps clinicians deliver predictable outcomes while reducing the need for multiple patient visits. For many patients, that means receiving a permanent restoration in a single appointment, avoiding temporary restorations, and returning to their normal routines sooner.

“Reaching five million CEREC chairside restorations is a powerful example of what sustained digital adoption can achieve at scale,” said Mark Bezjak, Group Vice President, Americas at Dentsply Sirona. “Our collaboration with PDS Health reflects a shared commitment to equipping clinicians with connected technologies that improve workflow efficiency, support clinical confidence, and enhance the patient experience.”

Across PDS Health’s practices, the integration of CEREC technology into everyday restorative workflows has helped enable:

Greater efficiency and consistency in restorative care deliverySame-day restorative capabilities, reducing the need for multiple appointmentsDigital workflows that support predictable restorative outcomes and efficient clinical decision-makingA more connected and convenient patient experience This milestone further highlights the growing role of digital dentistry in helping practices deliver scalable, high-quality care with greater consistency over time. It also reflects continued investment by PDS Health and Dentsply Sirona to advancing technologies that support clinicians, strengthen workflows, and improve the patient experience while shaping the future of restorative dentistry.

Dentsply Sirona Contact Information

Investors:
Wade Moody
Senior Manager, Investor Relations
[email protected]

Press:
Marion Par-Weixlberger
Vice President Public Relations, Corporate Communications & Brand
[email protected]

About Dentsply Sirona

Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona’s innovative products provide, high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona’s headquarters is located in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

PDS Health Contact Information:
Ellen Driscoll | Director, Enterprise Communications
[email protected]

About PDS Health

PDS Health® continues the journey started by Pacific Dental Services® in 1994, with a vision to redefine healthcare through the integration of dental and medical services. Its approach, centered on the connection between oral health and overall health, aims to create healthier, happier patients and set new benchmarks in the healthcare industry. As a leading provider of integrated healthcare support, the company delivers a broad spectrum of services to dental, dental specialties, and medical providers, enhancing operations and care delivery for clinicians across the U.S. For more information about PDS Health and its vision, visit pdshealth.com.

Posted by Defense World Staff on Apr 5th, 2026

DENTSPLY SIRONA Inc. (NASDAQ:XRAY – Get Free Report) has been assigned an average rating of “Hold” from the fifteen research firms that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $14.4167.

XRAY has been the topic of several research analyst reports. Wells Fargo & Company lifted their price target on DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th. UBS Group decreased their target price on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Zacks Research raised shares of DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Barclays started coverage on shares of DENTSPLY SIRONA in a report on Monday, December 8th. They set an “underweight” rating and a $12.00 price target on the stock. Finally, Mizuho upped their price target on shares of DENTSPLY SIRONA from $14.00 to $16.00 and gave the company a “neutral” rating in a research report on Monday, March 2nd.

Check Out Our Latest Report on DENTSPLY SIRONA

DENTSPLY SIRONA Stock Performance XRAY stock opened at $11.63 on Friday. The company has a 50-day simple moving average of $12.47 and a 200 day simple moving average of $12.14. The company has a market capitalization of $2.32 billion, a P/E ratio of -3.88, a PEG ratio of 1.37 and a beta of 0.99. The company has a quick ratio of 1.03, a current ratio of 1.51 and a debt-to-equity ratio of 1.50. DENTSPLY SIRONA has a fifty-two week low of $9.85 and a fifty-two week high of $17.18.

DENTSPLY SIRONA (NASDAQ:XRAY – Get Free Report) last released its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). The company had revenue of $961.00 million for the quarter, compared to analyst estimates of $926.40 million. DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.26 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Sell-side analysts predict that DENTSPLY SIRONA will post 1.84 earnings per share for the current fiscal year.

Insiders Place Their Bets In other DENTSPLY SIRONA news, Director Gregory T. Lucier purchased 15,000 shares of the stock in a transaction dated Monday, March 9th. The shares were acquired at an average price of $12.45 per share, for a total transaction of $186,750.00. Following the completion of the acquisition, the director owned 65,000 shares of the company’s stock, valued at $809,250. This represents a 30.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James D. Forbes purchased 5,000 shares of the company’s stock in a transaction that occurred on Monday, March 9th. The shares were acquired at an average cost of $12.48 per share, for a total transaction of $62,400.00. Following the completion of the transaction, the director directly owned 10,000 shares of the company’s stock, valued at $124,800. This trade represents a 100.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 70,000 shares of company stock valued at $956,437 in the last 90 days. Corporate insiders own 0.50% of the company’s stock.

Institutional Investors Weigh In On DENTSPLY SIRONA Institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of DENTSPLY SIRONA in the 1st quarter valued at about $26,000. Goldman Sachs Group Inc. grew its position in DENTSPLY SIRONA by 827.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after purchasing an additional 2,172,343 shares in the last quarter. Empowered Funds LLC grew its position in DENTSPLY SIRONA by 8.8% during the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after purchasing an additional 1,320 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in DENTSPLY SIRONA by 7.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock valued at $8,860,000 after buying an additional 41,579 shares during the period. Finally, Focus Partners Wealth lifted its position in DENTSPLY SIRONA by 59.1% in the 1st quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock worth $376,000 after buying an additional 9,355 shares in the last quarter. 95.70% of the stock is currently owned by institutional investors and hedge funds.

About DENTSPLY SIRONA (Get Free Report)

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

Further Reading Five stocks we like better than DENTSPLY SIRONA

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEDT Midstream, Inc. (NYSE:DTM) Receives Average Recommendation of “Hold” from Brokerages

NEXT HEADLINE »Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of “Moderate Buy” from Analysts

Posted by Defense World Staff on Apr 25th, 2026

Cwm LLC reduced its stake in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY – Free Report) by 54.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 191,766 shares of the medical instruments supplier’s stock after selling 228,704 shares during the quarter. Cwm LLC owned approximately 0.10% of DENTSPLY SIRONA worth $2,192,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. AQR Capital Management LLC lifted its stake in DENTSPLY SIRONA by 109.8% in the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after acquiring an additional 6,970,086 shares during the period. Armistice Capital LLC lifted its stake in DENTSPLY SIRONA by 1,044.0% in the third quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock worth $72,790,000 after acquiring an additional 5,234,587 shares during the period. Jacobs Levy Equity Management Inc. raised its holdings in DENTSPLY SIRONA by 662.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock worth $58,480,000 after purchasing an additional 4,003,606 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in DENTSPLY SIRONA by 827.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after purchasing an additional 2,172,343 shares in the last quarter. Finally, Brickwood Asset Management LLP raised its holdings in DENTSPLY SIRONA by 5,515.8% in the third quarter. Brickwood Asset Management LLP now owns 1,524,074 shares of the medical instruments supplier’s stock worth $19,340,000 after purchasing an additional 1,496,935 shares in the last quarter. 95.70% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling In other news, Director James D. Forbes acquired 5,000 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were acquired at an average price of $12.48 per share, with a total value of $62,400.00. Following the purchase, the director directly owned 10,000 shares of the company’s stock, valued at $124,800. This trade represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Gregory T. Lucier acquired 15,000 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were purchased at an average cost of $12.45 per share, for a total transaction of $186,750.00. Following the purchase, the director directly owned 65,000 shares in the company, valued at approximately $809,250. This trade represents a 30.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 70,000 shares of company stock worth $956,437 in the last ninety days. Corporate insiders own 0.50% of the company’s stock.

Analyst Ratings Changes XRAY has been the subject of a number of recent research reports. Mizuho boosted their target price on shares of DENTSPLY SIRONA from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Monday, March 2nd. Bank of America upgraded shares of DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and upped their price objective for the company from $13.00 to $17.00 in a report on Thursday, February 19th. Weiss Ratings restated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a report on Monday. Zacks Research upgraded shares of DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. Finally, Citigroup started coverage on shares of DENTSPLY SIRONA in a report on Wednesday, April 15th. They set a “sell” rating and a $10.00 price objective on the stock. Three research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, DENTSPLY SIRONA has an average rating of “Hold” and a consensus target price of $14.08.

Check Out Our Latest Stock Report on XRAY

DENTSPLY SIRONA Stock Performance NASDAQ XRAY opened at $11.91 on Friday. The stock has a 50-day simple moving average of $12.23 and a two-hundred day simple moving average of $12.05. The firm has a market capitalization of $2.38 billion, a P/E ratio of -3.97, a PEG ratio of 1.40 and a beta of 0.99. DENTSPLY SIRONA Inc. has a fifty-two week low of $9.85 and a fifty-two week high of $17.18. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.03 and a current ratio of 1.51.

DENTSPLY SIRONA (NASDAQ:XRAY – Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). The company had revenue of $961.00 million during the quarter, compared to analysts’ expectations of $926.40 million. DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.26 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, equities analysts forecast that DENTSPLY SIRONA Inc. will post 1.43 earnings per share for the current year.

DENTSPLY SIRONA Profile (Free Report)

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

See Also Five stocks we like better than DENTSPLY SIRONA Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY – Free Report).

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECwm LLC Has $2.12 Million Position in Hayward Holdings, Inc. $HAYW

NEXT HEADLINE »Farther Finance Advisors LLC Raises Stock Position in Vanguard Long-Term Corporate Bond ETF $VCLT

The market expects Becton Dickinson (BDX - Free Report) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 7. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus EstimateThis medical device manufacturer is expected to post quarterly earnings of $2.77 per share in its upcoming report, which represents a year-over-year change of -17.3%.

Revenues are expected to be $4.67 billion, down 11.5% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.56% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Becton Dickinson?For Becton Dickinson, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.24%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination makes it difficult to conclusively predict that Becton Dickinson will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Becton Dickinson would post earnings of $2.82 per share when it actually produced earnings of $2.91, delivering a surprise of +3.19%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Becton Dickinson doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

An Industry Player's Expected ResultsAnother stock from the Zacks Medical - Dental Supplies industry, Dentsply International (XRAY - Free Report) , is soon expected to post earnings of $0.28 per share for the quarter ended March 2026. This estimate indicates a year-over-year change of -34.9%. Revenues for the quarter are expected to be $840.06 million, down 4.4% from the year-ago quarter.

The consensus EPS estimate for Dentsply has been revised 3.9% lower over the last 30 days to the current level. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of +1.98%.

This Earnings ESP, combined with its Zacks Rank #3 (Hold), suggests that Dentsply will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

May 04, 2026 17:00 ET  | Source: DENTSPLY SIRONA Inc.

CHARLOTTE, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Dentsply Sirona (Nasdaq: XRAY), the world’s largest diversified manufacturer of professional dental products and technologies, today announced an enhanced distribution agreement with Atlanta Dental Supply, under which Atlanta Dental will begin offering Dentsply Sirona’s connected technology solutions portfolio in the United States as of August 1.

The expanded agreement strengthens Dentsply Sirona’s U.S. go-to-market strategy by extending its digital dentistry offerings through a well-established, independent regional distributor with deep customer relationships across the Southeast.

Atlanta Dental Supply, 100% employee-owned, founded in 1868, is a privately held dental distributor serving practices with dental supplies, equipment, technology, and dedicated service support. Under the enhanced agreement, Atlanta Dental Supply will begin offering key digital dentistry technologies from Dentsply Sirona, including the CEREC system, intraoral scanning, and digital imaging solutions.

“Expanding access to our digital dentistry technologies through trusted distribution partners is a core element of our commercial strategy,” said Mark Bezjak, Group Vice President Americas, Dentsply Sirona. “Atlanta Dental Supply’s regional scale, service infrastructure, and long-standing relationships with independent practices make them a strong partner for reaching customers where and how they prefer to buy.”

The agreement supports Dentsply Sirona’s focus on disciplined distribution expansion, customer centricity, and localized commercial execution through established partners.

Registered brands, trade names and logos are used. Even in particular cases, when they appear without a TM or ®, all corresponding legal rules and provisions apply. All rights are retained by Dentsply Sirona. Clinicians may have been compensated for use of their experiences and testimonials.

About Dentsply Sirona

Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona’s innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

Contact Information:

Dentsply Sirona Press Contact:
Marion Par-Weixlberger
Vice President, Corporate Communications, Public Relations & Brand
[email protected] | www.dentsplysirona.com

Dentsply Sirona Investors:
Wade Moody
Senior Manager, Investor Relations
[email protected]

Dentsply International (XRAY - Free Report) came out with quarterly earnings of $0.27 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.43 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -3.95%. A quarter ago, it was expected that this dental products manufacturer would post earnings of $0.28 per share when it actually produced earnings of $0.27, delivering a surprise of -3.57%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

Dentsply, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $880 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 5.12%. This compares to year-ago revenues of $879 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Dentsply shares have lost about 2% since the beginning of the year versus the S&P 500's gain of 5.2%.

What's Next for Dentsply?While Dentsply has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Dentsply was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.37 on $892.88 million in revenues for the coming quarter and $1.43 on $3.57 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

The Cooper Companies (COO - Free Report) , another stock in the same industry, has yet to report results for the quarter ended April 2026. The results are expected to be released on June 4.

This surgical and contact lens products maker is expected to post quarterly earnings of $1.10 per share in its upcoming report, which represents a year-over-year change of +14.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

The Cooper Companies' revenues are expected to be $1.05 billion, up 5.3% from the year-ago quarter.

DENTSPLY SIRONA Inc. (XRAY) Q1 2026 Earnings Call Transcript

May 20, 2026 16:15 ET  | Source: DENTSPLY SIRONA Inc.

CHARLOTTE, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the 2026 Stifel Jaws & Paws Conference. Management is scheduled to present on Wednesday, May 27, 2026, at 3:35 p.m. ET.

Investors and other interested parties will be able to access a live audio webcast and an audio webcast replay by visiting the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com.

About Dentsply Sirona

Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona’s innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

Contact Information

Investors:
Wade Moody
Senior Manager, Investor Relations
[email protected]

DENTSPLY SIRONA Inc. (XRAY) Presents at Stifel Jaws & Paws Conference 2026 Transcript

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Dentsply Sirona Inc. (NASDAQ: XRAY) breached their fiduciary duties to shareholders.

If you currently own Dentsply stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].

Why Your Participation Matters:

Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

Key Takeaways XRAY's 24-month Return-to-Growth plan targets ~$120M annual savings after ~$20M in Q1.DENTSPLY Sirona adds distributor wins, expands Atlanta Dental Supply ties; Benco installs first CEREC early.XRAY ramps R&D with Smart View-Detect ( 46% sensitivity), new endo products and an FDA-cleared dental MRI. DENTSPLY SIRONA (XRAY - Free Report) is well positioned for growth due to its new digital-implant workflow and continued focus on research and development. However, forex headwinds and demand softness in Europe remain a concern.

Shares of this Zacks Rank #3 (Hold) company have lost 12.2% year to date compared with the industry's 4.3% decline. The S&P 500 Index has gained 8.1% in the same time frame.

XRAY, with a market capitalization of $2.1 billion, is a global leader in the design, development, manufacturing and marketing of dental consumables, dental laboratory products, dental specialty products and consumable medical device products. It anticipates earnings to improve 5.9% over the next five years.

Image Source: Zacks Investment Research

Factors Favoring XRAY’s GrowthReturn-to-Growth Plan Creates a Clear Framework for Operational Recovery: DENTSPLY Sirona’s most important positive catalyst is the disciplined execution of its 24-month “Return-to-Growth” strategy. Management has already completed key organizational restructuring initiatives, expanded sales-force training, strengthened commercial leadership and improved distributor engagement.

The company generated approximately $20 million of operating expense savings in the first quarter, demonstrating that restructuring benefits are beginning to materialize. Management expects the broader restructuring program to deliver roughly $120 million in annual savings, with a larger contribution emerging in the second half of 2026 and beyond.

While revenue growth remains muted currently, the combination of cost rationalization, commercial reinvestment and improved accountability could significantly enhance earnings leverage if execution improves. The strategy provides a credible roadmap for restoring profitability and accelerating growth into 2027 and 2028.

Distribution Expansion Could Reignite U.S. Market Share Gains: Management repeatedly emphasized that restoring U.S. growth is the company’s top priority, and recent distributor wins suggest early progress. During the first quarter, DENTSPLY signed multiple new distribution agreements and expanded existing relationships, including a broader partnership with Atlanta Dental Supply. Early traction is already visible, with Benco installing its first CEREC system ahead of schedule.

These partnerships improve geographic reach, customer access and product availability without requiring substantial internal infrastructure expansion. Given that distributor inventory levels remain below historical averages, any normalization could further support future sales. If the company successfully leverages its broad portfolio across imaging, CAD/CAM, consumables and equipment, the enhanced distribution network may become a meaningful growth driver and help the company regain competitive positioning in key U.S. markets.

Innovation Pipeline Strengthens Competitive Positioning: DENTSPLY is increasing R&D investment despite near-term earnings pressure, signaling confidence in future product opportunities. The recently launched Smart View-Detect, an AI-enabled diagnostic platform, improves detection sensitivity by approximately 46% compared with unaided review.

Other new products include latest endodontic solutions and an FDA-cleared dental MRI system. These innovations align with broader industry trends toward digital workflows, AI-assisted diagnostics and integrated treatment planning. Management also highlighted enterprise AI deployment across commercial and operational functions.

Although the financial contributions from these products may not become meaningful until 2027 or later, they enhance the company’s technology leadership and provide avenues for differentiation against lower-cost competitors. Sustained innovation could improve customer retention while expanding penetration within digitally connected dental practices.

Downsides for XRAYCore Business Trends Remain Weak Across Multiple Segments: While management emphasized future recovery initiatives, current operating performance remains challenging. On a constant-currency basis, revenues declined 6.7%, with weakness spanning several major businesses, including Essential Dental Solutions (“EDS”), Orthodontic and Implant Solutions (“OIS”) and parts of Connected Technology Solutions (“CTS”).

Implant volumes declined across all regions, while EDS posted a significant 7.2% decline, reflecting softer demand and potential dealer destocking activity. The breadth of these declines suggests that the turnaround remains in its early stages and is yet to materially improve the market performance. Until revenue stabilization becomes visible across key segments, investors may remain skeptical regarding management’s ability to convert strategic initiatives into sustainable top-line growth.

Margin Pressure From Tariffs, Mix and Volume Absorption: Profitability deteriorated materially during the first quarter as adjusted EBITDA margin contracted approximately 430 basis points. Management cited multiple headwinds, including tariffs, unfavorable product mix, lower manufacturing absorption and weakness in high-margin consumables. EDS, one of the company’s most profitable segments, experienced notable declines, creating additional margin pressure.

Although management expects some tariff relief and operational improvements later in the year, many of these challenges remain outside the company’s direct control. Continued geopolitical uncertainty, elevated freight costs and inflationary pressures could delay margin recovery. If revenue growth fails to accelerate sufficiently, the anticipated benefits from restructuring efforts may be partially offset by ongoing cost headwinds.

Implant Franchise Underperforming:The performance of its implant business, which remains one of the company’s most strategically important franchises, remains unsatisfactory. Implant sales declined across all geographic regions despite management’s view that the portfolio contains some of the strongest products in the market. The issue appears to be less about product quality and more about execution, clinical education and sales effectiveness.

However, execution-related challenges can be difficult to resolve quickly, particularly in highly competitive dental implant markets. Because implants represent a key component of management’s growth strategy, prolonged weakness could undermine broader turnaround efforts and limit the company’s ability to achieve above-market growth over the next several years.

XRAY’s Estimate TrendThe Zacks Consensus Estimate for 2026 revenues is pegged at $3.58 billion, indicating a 2.7% decrease from the 2025 level.

The consensus mark for adjusted earnings per share is pinned at $1.42 for 2026, indicating an 11.3% year-over-year decline.

Stocks to ConsiderSome better-ranked stocks from the same medical industry are Align Technology (ALGN - Free Report) , West Pharmaceutical Services (WST - Free Report) and Cardinal Health (CAH - Free Report) .

Align Technology, carrying a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 10.3%. ALGN’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 7.80%. You can see the complete list of today’s Zacks #1 Rank stocks here.

ALGN’s shares have gained 9.2% against the industry’s 4.2% decline so far this year.

West Pharmaceutical, currently carrying a Zacks Rank of 1, has an estimated long-term growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 19.37%.

West Pharmaceutical’s shares have gained 20.2% against the industry’s 4.2% decline year to date.

Cardinal Health, currently carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%.

CAH’s shares have gained 5.2% against the industry’s 4.2% decline so far this year.